• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Losmapimod does not improve cardiovascular outcomes after myocardial infarction

byDaniel FisherandMichael Milligan
April 6, 2016
in Cardiology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Losmapimod, when administered to patients after a myocardial infarction (MI), was not effective in reducing subsequent severe cardiovascular events, including death.

2. Losmapimod did lower certain biomarkers, such as brain natriuretic peptide (BNP) and C-reactive protein (CRP), though these values tended to return to normal after prolonged treatment.

Evidence Rating Level: 1 (Excellent)

Study Rundown: After an MI, heightened levels of inflammation have been shown to further damage cardiac tissue, leading to poorer cardiovascular outcomes. A novel p38 mitogen-activated protein kinase (MAPK) inhibitor, losmapimod, was shown to reduce certain inflammatory markers after MI in clinical settings. This multisite, randomized controlled trial, sought to determine what effects this therapy might have on cardiovascular outcomes. Results showed that losmapimod, administered for 24 weeks after an MI, was not associated with a reduction in severe cardiovascular events, including subsequent MI, recurrent ischemia leading to revascularization, or cardiovascular death. In addition, many secondary endpoints of poor cardiovascular health remained similarly elevated in both treatment and control groups. Despite stratifying results by sex, age, non-ST elevation myocardial infarction (NSTEMI) or STEMI, prior treatment strategy, and other factors, losmapimod continued to show no clinical benefit over placebo. Despite this lack of clinical efficacy, losmapimod administration was correlated with decreased CRP levels in the acute setting, and reductions in BNP for up to 12 weeks after MI. However, both of these biomarkers returned to the same levels as those in the placebo group by the end of the study. Likewise, there were no differences in other adverse outcomes or side effects. The results of this rigorously designed study strongly suggests that losmapimod monotherapy is unlikely to be clinically beneficial for patients after an MI. However, further studies might explore its use combined with other anti-inflammatory agents.

Click to read the study in JAMA

Relevant Reading: Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial

RELATED REPORTS

Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule

Coronary CT-angiography-guided management improves outcomes in patients with stable chest pain

Spironolactone ineffective for patients with preserved ejection fraction after myocardial infarction

In-Depth [randomized controlled trial]: A total of 3490 patients at 322 sites in 34 countries who presented with NSTEMI or STEMI were randomized to receive losmapimod (7.5 mg BID) or placebo for 24 weeks. Exclusion criteria included clinical instability, acute or chronic liver or kidney disease, opportunistic infection, or NYHA class III or higher heart failure at time of MI. There was no difference in primary endpoints of cardiovascular death, recurrent MI, or severe recurrent ischemia requiring revascularization between treatment and placebo groups. Secondary endpoints, including hospitalization for heart failure, stroke, coronary artery disease, or stent thrombosis, were also similar. No differences were observed when patients were grouped by age, sex, prior MI, chronic kidney disease, NSTEMI vs STEMI, prior PCI or CABG, planned versus actual treatment strategy for MI, time from randomization to PCI, or number of predictors of cardiovascular risk. Losmapimod was able to reduce CRP at 4 weeks and BNP at 12 weeks after MI, but both levels returned to placebo group levels after these time points. No difference in adverse events or side effects were noted.

 

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular diseasemyocardial infarction
Previous Post

Bariatric surgery associated with sustained improvements in mobility and joint pain

Next Post

WIC revisions associated with higher diet quality in children

RelatedReports

Pulmonary MRI with ultrashort echo time is comparable to pulmonary CT
Pharma

Merck’s Winrevair: Pulmonary arterial hypertension drug shows success ahead of schedule

March 25, 2025
Physician visual assessment of coronary stenosis severity overestimates quantitative coronary angiography
Cardiology

Coronary CT-angiography-guided management improves outcomes in patients with stable chest pain

March 12, 2025
Cardiology

Spironolactone ineffective for patients with preserved ejection fraction after myocardial infarction

March 4, 2025
Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease
Cardiology

Catheter-guided aortic valve replacement and angioplasty has favorable outcomes compared to surgical intervention

February 11, 2025
Next Post
WIC revisions associated with higher diet quality in children

WIC revisions associated with higher diet quality in children

Endostatin directly binds androgen receptors to treat prostate cancer [PreClinical]

Statins reduce the risk of cardiovascular disease in intermediate risk patients: The HOPE-3 trial

Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas

Radiation plus chemotherapy confers survival benefit compared to radiation alone in low-grade gliomas

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Use of psychiatric medications may be associated with a higher risk of amyotrophic lateral sclerosis
  • Nivolumab plus ipilimumab improves survival over lenvatinib or sorafenib in liver cancer
  • Dapagliflozin may improve outcomes in patients with metabolic dysfunction-associated steatohepatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.